In the following video, Motley Fool health-care analyst David Williamson continues his look at the top-performing health-care stocks of last month. Here, he examines Furiex (UNKNOWN:UNKNOWN), up a whopping 67% for January, most of which was made in a single day. Three important FDA approvals for type 2 diabetes drugs were granted to the Japanese drugmaker Takeda this past month, with Furiex set to receive a $25 million milestone payment from the drugs, as well as sales royalties and further potential milestone payments, which fueled investor enthusiasm over the company this past month. David tells us some of the history of Furiex, and what investors should be watching for in its pipeline.